Suppliers and packagers for generic pharmaceutical drug: ESOMEPRAZOLE SODIUM

ESOMEPRAZOLE SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eugia Pharma	ESOMEPRAZOLE SODIUM	esomeprazole sodium	INJECTABLE;INTRAVENOUS	204657	ANDA	Eugia US LLC	55150-185-05	10 VIAL in 1 CARTON (55150-185-05) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2016-08-10
Gland	ESOMEPRAZOLE SODIUM	esomeprazole sodium	INJECTABLE;INTRAVENOUS	203349	ANDA	Gland Pharma Limited	68083-451-10	10 VIAL in 1 CARTON (68083-451-10) / 5 mL in 1 VIAL (68083-451-01)	2020-04-01
Gland	ESOMEPRAZOLE SODIUM	esomeprazole sodium	INJECTABLE;INTRAVENOUS	203349	ANDA	Gland Pharma Limited	68083-452-10	10 VIAL in 1 CARTON (68083-452-10) / 5 mL in 1 VIAL (68083-452-01)	2020-04-01

Esomeprazole Sodium Supply Chain Analysis

Last updated: February 19, 2026

Key Suppliers for Esomeprazole Sodium Manufacturing

Manufacturing esomeprazole sodium, the S-enantiomer of omeprazole, requires specialized chemical synthesis and adherence to stringent pharmaceutical quality standards. The global supply chain for esomeprazole sodium active pharmaceutical ingredient (API) and its key intermediates is dominated by a select group of manufacturers primarily located in India and China. These suppliers provide critical raw materials and the finished API to generic drug producers and, in some cases, to the originator company through contract manufacturing agreements.

The primary active pharmaceutical ingredient (API) for esomeprazole sodium is typically manufactured through multi-step organic synthesis. Key starting materials and intermediates include compounds like 2-(chloromethyl)-3,5-dimethyl-4-methoxypyridine hydrochloride and 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. The enantiomeric purity of the final product is crucial, necessitating stereoselective synthesis or resolution techniques.

Major global suppliers of esomeprazole sodium API include:

• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Divi's Laboratories Limited
• Laurus Labs Limited
• Hetero Labs Limited
• Venkateswara Rao & Company (VRC)
• Zydus Lifesciences Ltd. (formerly Cadila Healthcare)
• Jiangsu Hengrui Medicine Co., Ltd. (China)
• Zhejiang NHU Co., Ltd. (China)

These companies often possess integrated manufacturing capabilities, allowing them to control production from early-stage intermediates to the final API. Their regulatory compliance, including Good Manufacturing Practices (GMP) certifications from agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others, is a critical factor for pharmaceutical companies sourcing these materials for regulated markets.

What are the Key Intermediates and Raw Materials in Esomeprazole Sodium Synthesis?

The synthesis of esomeprazole sodium involves several critical chemical intermediates. The precise route can vary between manufacturers, impacting the specific intermediates required. However, common building blocks and reagents are essential.

The core structure of esomeprazole is derived from a substituted pyridine and a substituted benzimidazole. Key intermediates often include:

• 2-(Chloromethyl)-3,5-dimethyl-4-methoxypyridine hydrochloride: This pyridine derivative provides one half of the esomeprazole molecule. Its synthesis typically involves multiple steps starting from simpler pyridine precursors.
• 5-Methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylthio]-1H-benzimidazole: This thioether intermediate is a direct precursor that undergoes oxidation to form the sulfinyl group. The stereochemistry of this oxidation is critical for obtaining the S-enantiomer.
• Sodium hydroxide: Used for forming the sodium salt of esomeprazole.
• Oxidizing agents: Such as meta-chloroperoxybenzoic acid (m-CPBA) or hydrogen peroxide with a catalyst, are used to convert the thioether to the sulfoxide. Stereoselective oxidation is often employed to favor the formation of the S-enantiomer directly. Alternatively, racemic omeprazole can be synthesized and then resolved.
• Chiral resolving agents: If resolution is used, specific chiral acids or bases are required to separate the S-enantiomer from the R-enantiomer. Examples include chiral amines.
• Solvents: A variety of organic solvents are used throughout the synthesis, including methanol, ethanol, dichloromethane, toluene, and ethyl acetate.
• Catalysts: Specific catalysts may be used for various reaction steps, including coupling reactions and oxidation.

The quality and consistency of these intermediates are paramount. Impurities carried forward from early stages can impact the purity and efficacy of the final API. Manufacturers specializing in these specific chemical building blocks are also integral to the esomeprazole sodium supply chain. These may include companies focused on heterocyclic chemistry and custom synthesis.

How is the Purity and Quality of Esomeprazole Sodium API Ensured?

Ensuring the purity and quality of esomeprazole sodium API is governed by stringent pharmacopeial standards and regulatory requirements. Manufacturers must adhere to Good Manufacturing Practices (GMP) throughout the production process.

Key aspects of quality assurance and control include:

• Impurity Profiling: Rigorous testing for related substances, degradation products, and residual solvents. Specific impurities, such as the R-enantiomer (omeprazole) and potential genotoxic impurities, must be controlled below defined limits, typically specified by ICH guidelines and pharmacopeias (e.g., USP, EP, JP).
• Enantiomeric Purity: Esomeprazole sodium is the S-enantiomer of omeprazole. High enantiomeric excess (ee) is required, usually above 99.5%. Chiral High-Performance Liquid Chromatography (HPLC) is the standard method for determining enantiomeric purity.
• Assay: Determination of the active content of esomeprazole sodium, typically performed by HPLC. The assay must fall within a specified range, often 98.0% to 102.0% on an anhydrous basis.
• Water Content: Measured using Karl Fischer titration, as water can affect stability.
• Heavy Metals: Testing for the presence of heavy metals is a standard requirement.
• Microbiological Limits: For sterile drug products, API manufacturers must also meet stringent microbiological specifications.
• Stability Studies: Comprehensive studies are conducted under various storage conditions (temperature, humidity) to establish shelf life and appropriate storage recommendations.
• Validation: All analytical methods used for testing must be validated according to ICH guidelines to ensure accuracy, precision, specificity, linearity, and robustness.
• Regulatory Filings: API manufacturers must maintain Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) with regulatory authorities, documenting their manufacturing process, quality controls, and impurity profiles. These filings are reviewed by regulatory agencies as part of drug product approval.

Companies that supply esomeprazole sodium API typically undergo regular inspections by regulatory bodies such as the FDA, EMA, and national competent authorities to ensure ongoing compliance with GMP.

What are the Regulatory Requirements for Esomeprazole Sodium API Suppliers?

Suppliers of esomeprazole sodium API must comply with a complex web of international and national regulatory requirements to ensure product safety, efficacy, and quality for use in pharmaceutical formulations.

Primary regulatory considerations include:

• Good Manufacturing Practices (GMP): Adherence to current GMP (cGMP) standards is mandatory. These guidelines cover all aspects of production and quality control, including personnel, facilities, equipment, raw material sourcing, manufacturing processes, packaging, labeling, and distribution. Key GMP regulations include ICH Q7 for APIs.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Suppliers must file detailed DMFs (in the US) or ASMFs (in Europe and other regions) with regulatory agencies. These documents contain proprietary information about the API's manufacturing process, controls, and specifications. Pharmaceutical companies reference these filings in their drug product applications.
• Pharmacopeial Compliance: The API must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These monographs define standards for identity, strength, quality, and purity.
• International Council for Harmonisation (ICH) Guidelines: Suppliers are expected to follow ICH guidelines, particularly:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q3A/B/C/D: Guidelines on impurities (new drug substances, new drug products, residual solvents, elemental impurities).
  • ICH Q1A-Q1F: Guidelines on stability testing.
  • ICH Q2: Validation of analytical procedures.
• Site Inspections: API manufacturing facilities are subject to inspections by regulatory authorities (e.g., FDA, EMA, PMDA) to verify compliance with GMP and the information submitted in DMFs/ASMFs. Successful inspection outcomes are critical for market access.
• Change Control: Any changes to the manufacturing process, specifications, or testing methods must be evaluated for their impact on API quality and, if significant, reported to regulatory authorities and customers.
• Country-Specific Registrations: Depending on the target market, suppliers may need to comply with specific national registration requirements and obtain import permits.
• Environmental, Health, and Safety (EHS) Regulations: Manufacturers must also comply with local and international EHS regulations pertaining to chemical manufacturing.

The robustness of a supplier's regulatory compliance program, evidenced by successful audits and up-to-date filings, is a key differentiator for pharmaceutical companies making sourcing decisions.

What are the Risks and Considerations When Sourcing Esomeprazole Sodium?

Sourcing esomeprazole sodium API and its intermediates involves several inherent risks and considerations that pharmaceutical companies must carefully manage to ensure supply chain security, product quality, and cost-effectiveness.

Key Risks and Considerations:

• Supply Chain Disruption:
  • Geopolitical Instability: Concentration of manufacturing in specific regions (primarily India and China) exposes the supply chain to risks from trade disputes, political unrest, or natural disasters.
  • Single Sourcing: Over-reliance on a single supplier for the API or critical intermediates creates vulnerability.
  • Logistical Challenges: Transportation delays, customs issues, and fluctuations in shipping costs can impact timely delivery.
• Quality and Regulatory Compliance:
  • GMP Non-Compliance: A supplier's failure to maintain GMP standards can lead to product recalls, regulatory actions (e.g., import alerts), and significant financial penalties.
  • Substandard Quality: Inconsistent API quality, including unacceptable impurity levels or incorrect enantiomeric purity, can compromise the safety and efficacy of the final drug product.
  • Changes in Regulatory Landscape: Evolving regulatory expectations regarding impurity control or data integrity can necessitate costly process adjustments for suppliers.
• Intellectual Property (IP) and Patent Landscape:
  • Patent Expirations and Litigation: While the patent for esomeprazole (Nexium) has expired in major markets, understanding the ongoing patent landscape for specific manufacturing processes or formulations is crucial to avoid infringement.
  • Counterfeit Products: The risk of counterfeit API entering the supply chain, particularly in less regulated channels, is a significant concern.
• Cost and Pricing Volatility:
  • Raw Material Price Fluctuations: The cost of key starting materials can fluctuate based on global supply and demand, impacting API pricing.
  • Currency Exchange Rates: For international sourcing, currency volatility can affect the landed cost of the API.
  • Competitive Landscape: The number of API manufacturers and the intensity of competition influence pricing strategies.
• Supplier Viability and Financial Stability:
  • Financial Distress: A supplier facing financial difficulties may experience production disruptions or a decline in quality standards.
  • Mergers and Acquisitions: Consolidation within the API manufacturing sector can alter supply dynamics and relationships.
• Environmental and Social Governance (ESG):
  • Sustainability Practices: Increasing scrutiny on the environmental impact of chemical manufacturing, including waste management and energy consumption, may influence supplier selection.
  • Labor Practices: Ensuring ethical labor practices throughout the supply chain is becoming a greater consideration.

Mitigation Strategies:

• Dual/Multi-Sourcing: Establishing relationships with multiple qualified suppliers for critical APIs and intermediates.
• Robust Supplier Qualification Programs: Implementing thorough audits, quality agreements, and ongoing performance monitoring.
• Supply Chain Mapping and Transparency: Understanding the entire supply chain, including tier-2 and tier-3 suppliers.
• Inventory Management: Maintaining strategic inventory levels for critical raw materials and finished API.
• Contractual Safeguards: Including clauses in supply agreements that address quality, delivery, and intellectual property protection.
• Regular Audits and Site Visits: Conducting frequent quality audits of manufacturing facilities.
• Staying Abreast of Regulatory Changes: Proactive engagement with regulatory updates and industry best practices.

Key Takeaways

• The global supply of esomeprazole sodium API is concentrated among a limited number of manufacturers, primarily in India and China.
• Key intermediates, such as 2-(chloromethyl)-3,5-dimethyl-4-methoxypyridine hydrochloride and sulfur-containing benzimidazole derivatives, are critical to the synthesis.
• Stringent quality control, including enantiomeric purity testing and impurity profiling, is mandated by pharmacopeial standards and regulatory bodies.
• API suppliers must adhere to cGMP, maintain comprehensive DMFs/ASMFs, and undergo regular regulatory inspections.
• Sourcing risks include supply chain disruptions, quality non-compliance, regulatory changes, and cost volatility, necessitating dual-sourcing and robust supplier qualification programs.

Frequently Asked Questions

1. What is the typical enantiomeric purity requirement for esomeprazole sodium API? The S-enantiomer, esomeprazole, must typically have an enantiomeric excess (ee) of 99.5% or higher.

2. Which regulatory bodies are most influential for esomeprazole sodium API suppliers? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the most influential, alongside national regulatory agencies in other major markets like Japan (PMDA) and Brazil (ANVISA).

3. Can the R-enantiomer (omeprazole) be present as an impurity in esomeprazole sodium API? Yes, the R-enantiomer is a critical impurity that must be controlled to very low levels, typically below 0.5% or as defined by specific pharmacopeial monographs or regulatory filings.

4. What are the primary geographical hubs for esomeprazole sodium API manufacturing? India and China are the dominant manufacturing locations for esomeprazole sodium API, with a significant presence of companies holding established regulatory approvals.

5. How do supply chain disruptions in raw material production impact esomeprazole sodium API pricing? Disruptions in the supply of critical starting materials or intermediates can lead to increased raw material costs, which are then passed on to API manufacturers and can result in higher esomeprazole sodium API pricing and potential supply shortages.

Citations

[1] United States Pharmacopeia. (n.d.). Esomeprazole Sodium. In USP-NF. Retrieved from USP-NF online database. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Esomeprazole Sodium. In Ph. Eur.. Retrieved from Ph. Eur. online database. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline Q3C(R6): Impurities: Guideline for Residual Solvents. [6] Aurobindo Pharma Limited. (n.d.). API Product List. Retrieved from Aurobindo Pharma official website. [7] Dr. Reddy's Laboratories Ltd. (n.d.). APIs. Retrieved from Dr. Reddy's Laboratories official website. [8] Sun Pharmaceutical Industries Ltd. (n.d.). API Portfolio. Retrieved from Sun Pharma official website. [9] Divi's Laboratories Limited. (n.d.). API Products. Retrieved from Divi's Laboratories official website. [10] Jiangsu Hengrui Medicine Co., Ltd. (n.d.). Products. Retrieved from Hengrui Medicine official website.